Autologous Platelet Lysate Is an Alternative to Fetal Bovine Serum for Canine Adipose-Derived Mesenchymal Stem Cell Culture and Differentiation

The use of fetal bovine serum (FBS) in regenerative medicine raises serious ethical and scientific concerns. We have cultured and differentiated the canine mesenchymal stem cells (cMSCs) in five different media combinations of autologous platelet lysate (A-PL) and FBS; consisting of 0% A-PL and 10%...

Full description

Bibliographic Details
Main Authors: Usman Rashid, Evelyn Saba, Arfan Yousaf, Waleed Ahsan Tareen, Adeel Sarfraz, Man Hee Rhee, Mansur Abdullah Sandhu
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Animals
Subjects:
Online Access:https://www.mdpi.com/2076-2615/13/16/2655
Description
Summary:The use of fetal bovine serum (FBS) in regenerative medicine raises serious ethical and scientific concerns. We have cultured and differentiated the canine mesenchymal stem cells (cMSCs) in five different media combinations of autologous platelet lysate (A-PL) and FBS; consisting of 0% A-PL and 10% FBS (M-1), 2.5% A-PL and 7.5% FBS (M-2), 5% A-PL and 5% FBS (M-3), 7.5% A-PL and 2.5% FBS (M-4), and 10% A-PL and 0% FBS (M-5). The cMSCs were evaluated for their doubling time, differentiation efficiency, and expression of CD73, CD90, CD105, and PDGFRα. The mRNA expression of <i>NT5E</i>, <i>THY1</i>, <i>ENG</i>, <i>PPARγ</i>, <i>FABP4</i>, <i>FAS</i>, <i>SP7</i>, <i>BGLAP</i>, and <i>SPP1</i> was also assessed. The results indicated non-significant differences in cellular proliferation/viability; positive expression of surface markers, and PDGFRα with substantial adipo/osteogenic differentiation. The expression of adipogenic (<i>PPARγ</i>, <i>FABP4</i>, <i>FAS</i>), and osteogenic (<i>SP7</i>, <i>BGLAP</i>, <i>SPP1</i>) genes were higher (<i>p</i> < 0.05) in the M5 group. In conclusion, A-PL in cMSCs culture did not negatively affect cellular proliferation and viability but also enhanced their genetic potential for multilineage differentiation. Our results indicate that A-PL can be used as an alternative for FBS to develop potent cMSCs under good manufacturing practice protocol for regenerative medicine.
ISSN:2076-2615